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Abstract
 
Prior experiments in explants of human lymphoid tissue have demonstrated that human immu-
nodeficiency virus type 1 (HIV-1) productively infects diverse cellular targets including T cells
and tissue macrophages. We sought to determine the specific contribution of macrophages and
T cells to the overall viral burden within lymphoid tissue. To block infection of macrophages
selectively while preserving infection of T cells, we used viruses deficient for viral protein R
(Vpr) that exhibit profound replication defects in nondividing cells in vitro. We inoculated
tonsil histocultures with matched pairs of congenic viruses that differed only by the presence of
 
a wild-type or truncated 
 
vpr
 
 gene. Although these viruses exhibited no reduction in the infec-
tion or depletion of T cells, the ability of the Vpr-deficient R5 virus to infect tissue macro-
phages was severely impaired compared with matched wild-type R5 virus. Interestingly, the
Vpr-deficient R5 virus also exhibited a 50% reduction in overall virus replication compared
with its wild-type counterpart despite the fact that macrophages represent a small fraction of
the potential targets of HIV-1 infection in these tissues. Collectively, these data highlight the
importance of tissue macrophages in local viral burden and further implicate roles for CC che-
mokine receptor 5, macrophages, and Vpr in the life cycle and pathogenesis of HIV-1.
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Introduction
 
HIV-1 is a member of the lentivirus subfamily of retrovi-
ruses. Among the features that distinguish lentiviruses is
their productive infection of cells of the monocyte/mac-
rophage lineage. In addition to the 
 
gag
 
, 
 
pol
 
, and 
 
env
 
 genes
found in all retroviruses, the HIV-1 genome contains six
additional genes: 
 
tat
 
, 
 
rev
 
, 
 
vif
 
, 
 
vpr
 
, 
 
vpu,
 
 and 
 
nef
 
. These genes
confer upon HIV-1 a number of unique abilities, including
the capacity to infect noncycling cells. Viral protein R
 
(Vpr)
 
*
 
 in particular is known to play an important role in
facilitating infection of nondividing tissue macrophages (1–
 
6) as well as inducing G
 
2
 
 cell-cycle arrest in dividing T cells
(7–11). The 
 
vpr
 
 gene encodes a 96 amino acid, 14-kD nu-
cleophilic protein that is incorporated into mature virions
via an interaction with p6, a proteolytic subunit of the
p55
 
gag
 
 precursor (12–15). Although 
 
vpr
 
 is frequently deleted
during in vitro passaging, Vpr is believed to have numerous
functions that contribute to the establishment and patho-
genesis of HIV-1 infection in vivo (8, 16).
Unlike simple retroviruses, HIV-1 does not depend on
cellular division and the accompanying breakdown of the
nuclear envelope for productive infection (17, 18). It is be-
lieved that this special property is due to the concerted and
perhaps redundant activities of matrix (MA), integrase (IN),
the DNA flap, and Vpr. Specifically, both MA (19–21) and
IN (22–24) bound to the viral genome contain nuclear lo-
calization signals that target the preintegration complex
(PIC) to the nucleus via interactions with host nuclear im-
port machinery. The central DNA flap, a triple-stranded
helix that is common to retroviruses, may additionally con-
tribute to nuclear targeting through an unknown mecha-
nism (25). Vpr is also highly nucleophilic and utilizes a dis-
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tinct targeting strategy (1, 3–5, 26, 27). It contains two
nonoverlapping and unique nuclear localization signals that
likely contribute to the nuclear localization of the PIC (28,
29). Previous work has identified Vpr as a contributing fac-
tor in the infection of macrophages in vitro, which presum-
ably is linked to this nuclear localization function (2, 4, 6).
Vpr also causes G
 
2
 
 cell-cycle arrest in infected cells cul-
tured in vitro (7–11, 30). Expression of Vpr in some cell
types by transfection, transduction, or productive HIV-1 in-
fection is associated with inactivation of p34Cdc2 kinase,
leading to the accumulation of the cells in the G
 
2
 
 phase of
the cell-cycle (9, 11). The biologic significance of this arrest
during natural infection is not well understood. However,
studies have demonstrated that the HIV-1 LTR is most ac-
tive in the G
 
2
 
 phase, implying that G
 
2
 
 arrest may confer a
replicative advantage to viral species encoding a functional
Vpr (8, 31, 32). In vitro studies have also revealed that pro-
longed G
 
2
 
 arrest may induce apoptosis of the infected cell
(32–37), although others have not observed this effect (36,
38, 39). Thus, Vpr may variably potentiate or mediate
apoptosis, and this function seems to segregate with cell-
cycle arrest in mutagenesis studies (36). Based on these stud-
ies, it is speculated that Vpr contributes to HIV-mediated
immune destruction by promoting depletion of target cells.
To clarify the importance of Vpr to HIV replication and
subsequent pathogenesis, we employed a human lymphoid
histoculture model. This system is distinguished by its ca-
pacity to support the replication of HIV-1, HIV type 2
(HIV-2), or simian immunodeficiency virus (SIV) without
the need for exogenous cell activation or growth factors
(40–44). Consequently, this ex vivo system preserves the
diverse cell types and cellular activation and maturation
phenotypes found within lymphoid tissues in vivo. Spleen
and tonsil histocultures thus represent a valuable model in
which to study the cellular tropism and cytopathic potential
of these viruses in a physiologically relevant setting. We
therefore employed this model to determine in which cell
types Vpr plays a role in infection and to establish the con-
tribution of these cells to the viral burden within lymphoid
tissue. These studies reveal that while Vpr augments the in-
fection of macrophages, it does not contribute to the pro-
ductive infection of proliferating or resting T cells. Fur-
thermore, Vpr-deficient R5 viruses exhibit a significant
reduction in the extent of viral replication, emphasizing the
importance of tissue macrophages as a permissive reservoir
for viral replication in vivo. These findings suggest that
other host or viral factors may be responsible for the infec-
tion of resting lymphocytes and highlight the importance
of Vpr and CC chemokine receptor (CCR)5 coreceptor
specificity for HIV-1infection of tissue macrophages.
 
Materials and Methods
 
Cloning of Vpr-deficient Viruses.
 
The envelope genes deter-
mining CXCR4 (X4) or CCR5 (R5) preference were derived
from HIV-1 NL4–3 or HIV-1 BaL. The region extending from
the 5
 

 
 EcoR1 restriction endonuclease site located within the Vpr
gene to the NheI site distal to the V3 region within the envelope
 
gene were cloned from BaL and introduced into the NL4–3
proviral clone thereby creating the 107 strain (45). These se-
quences are sufficient to confer CCR5-tropism to 107. The Vpr
 

 
proviral clones were generated by introducing the AgeI to EcoRI
(within 
 
vpr
 
) fragment from the pNL4–3-derived partial proviral
clone p210–19 (46) (obtained from the National Institutes of
Health AIDS Research and Reference Reagent Program) into
the AgeI and EcoRI sites of the respective proviruses. This clon-
ing strategy preserved the 
 
pol
 
 and 
 
vif
 
 sequence identity between
NL4–3 and 107, truncated the Vpr product by introducing a
115-nucleotide deletion, and also introduced two stop codons af-
ter the 21st amino acid of Vpr and downstream of the Vif stop
codon in an otherwise isogenic virus.
 
Preparation of Viral Stocks.
 
Plasmids encoding NL4–3 or 107
were transfected into 293T cells using calcium phosphate precipi-
tation and 48 h later the resultant supernatants were centrifuged at
5,000 RPM for 10 min to remove cell debris and then aliquoted
for subsequent infection of histocultures. Virus stocks were nor-
malized for infectivity by determining the TCID
 
50
 
 on PHA-stim-
ulated PBMCs obtained from at least two separate donors as de-
scribed previously (40, 41).
 
Western Blot of Vpr.
 
For hemagglutinin-Vpr (HA-Vpr) con-
structs, equal number of 293T cells were transfected using cal-
cium phosphate and then harvested, pelleted, and lysed directly
with SDS loading buffer. Similar transfection efficiency was con-
firmed by cotransfection with pEGFP (CLONTECH Laborato-
ries, Inc.). Western blot was then performed with anti-HA mono-
clonal antibody (HA.11; Covance). For Vpr within HIV-1
virions, 300 ng of virus in 1 ml of media was concentrated by ul-
tra-centrifugation at 40,000 
 
g
 
 at 4
 

 
C for 1 h. The precipitate was
resuspended in loading buffer containing SDS and 
 

 
-mercapto-
ethanol and subjected to standard PAGE and blotted with anti-
bodies to p24 (Coulter) or Vpr (28).
 
Culture and Infection of Human Lymphoid Tissues Ex Vivo.
 
Human noninflammatory tonsil tissue removed during tonsillec-
tomy (provided by San Francisco General Hospital, Kaiser-San
Francisco and San Rafael, CA) were cut into 2–3 mm blocks and
placed into culture as described (40). Tissues were inoculated
within 24 h of preparation with viruses at 
 

 
50 TCID
 
50
 
/tissue
block. After 1- or 2-wk infections, cells were mechanically iso-
lated from infected and uninfected tissue and analyzed by flow
cytometry (see below). No significant differences in the ex vivo
behavior and HIV-1 or SIV permissivity of spleen or tonsil tissue
have been observed.
 
Assessment of CD4
 

 
 T Cell Infection by Flow Cytometry.
 
At the
indicated time points after inoculation (at peak infection, usually
1 wk after inoculation), dispersed cells from infected and unin-
fected lymphoid histocultures were immunostained for cell sur-
face markers CD4, CD62L, and CD45RA as described previ-
ously (47). Cells were then fixed in 1% paraformaldehyde and
subsequently permeabilized and immunostained for intracellular
CD4 and p24. 50,000 CD4
 

 
 lymphocytes were counted and the
data were analyzed with CELLQuest™ software (Becton Dickin-
son). To identify naive and memory subsets the following mAbs
were used from Becton Dickinson: anti-CD4 (clone SK7, allo-
phycocyanin conjugated, 1:20 dilution), and anti-CD62L (phy-
coerythrin, 1:20 dilution). The following antibody from BD
PharMingen was also used: anti-CD45RA (cychrome conju-
gated, 1:20 dilution). To identify infected cells, anti-p24 (fluores-
cein isothiocyanate, 1:100 dilution) from Beckman Coulter was
also used. Results are reported as the mean with SEM.
 
Flow Cytometric Analysis of Cellular Proliferation.
 
After cultur-
ing for 6 d in standard histoculture media supplemented with
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5-bromo-2
 

 
-deoxyuridine (BrdU; 50 
 

 
M; Sigma-Aldrich), lym-
phoid histocultures were stained for BrdU incorporation as de-
scribed previously (47). Briefly, after this incubation, cells were
dispersed and fixed and permeabilized overnight. Cells were
washed, treated with DNase, and then immunostained with
a combination of mAbs recognizing CD4 (Becton Dickin-
son, clone SK3, allophycocyanin conjugated, 1:40 dilution),
CD45RA (BD PharMingen, cychrome conjugated, 1:2.5 dilu-
tion), CD62L (Becton Dickinson, phycoerythrin conjugated,
1:20 dilution), and BrdU (BD PharMingen, fluorescein isothio-
cyanate conjugated, 1:2.5 dilution). 50,000 CD4
 

 
 lymphocytes
were then collected and analyzed by CELLQuest™.
 
Assessment of DNA Content by Flow Cytometry.
 
Cell-cycle
analysis for HA-Vpr constructs was performed by cotransfecting
pEGFP (CLONTECH Laboratories, Inc.) and HA-Vpr DNA
constructs into 293T cells in a 1:8 molar ratio to identify plasmid-
expressing cells. 36 h later cells were trypsinized, fixed in 2%
formaldehyde for 30 min, washed, and treated with 0.1 mg/ml
Ribonuclease (RNase) A (Sigma-Aldrich) and 10 mg/ml propid-
ium iodide in PBS for 30 min. Cellular DNA content in the
transfected (GFP
 

 
) and untransfected (GFP
 

 
) cells was assessed
using a FACScan™ flow cytometer. For analysis of infected and
uninfected lymphoid histocultures, cells were dispersed from the
tissue at the indicated time points post-inoculation (at peak infec-
tion, usually 1 wk after inoculation), and immunostained for the
cell surface marker CD4. Cells were then fixed in 1% paraformal-
dehyde and subsequently permeabilized and immunostained for
intracellular CD4 and p24. Samples were then incubated for 30
min in a solution of 0.01mM To-Pro-3 iodide (Molecular
Probes) and 0.1 mg/ml RNase A. 200,000 lymphocytes were
counted and the data were analyzed with CELLQuest™ and
FlowJo (Tree Star). The following mAb was used from Becton
Dickinson: anti-CD4 (clone SK7, phycoerythrin conjugated, 1:20
dilution). To identify infected cells, anti-p24 was also used.
 
Assessment of CD4
 

 
 T Cell Depletion by Flow Cytometry.
 
At
the indicated time points (usually 2 wk after inoculation), dis-
persed cells from infected and uninfected lymphoid histocultures
were immunostained for cell surface markers CD3, CD4, CD8,
and CCR5 as described previously (40, 41). 5,000–20,000 CD3
 

 
lymphocytes were counted and the data were analyzed with
CELLQuest™ and FlowJo. CD4
 

 
 T cell depletion was expressed
as the ratio of CD4
 

 
 to CD8
 

 
 T cells in infected relative to unin-
fected tissues as described previously (40, 41). The following
mAbs were used from Becton Dickinson: anti-CD3 (clone SK7,
allophycocyanin conjugated, 1:80 dilution), anti-CD4 (clone SK3,
fluorescein isothiocyanate conjugated, 1:20 dilution), and anti-
CD8 (clone SK1, phycoerythrin conjugated, 1:20 dilution). The
following antibody from BD PharMingen was also used: anti-
CCR5 (allophycocyanin conjugated, 1:20 dilution). Cell numbers
in infected tissues were normalized to those obtained for unin-
fected control tissues. Results are reported as the mean with SEM.
 
Assessment of Macrophage Infection by Flow Cytometry.
 
At the
indicated time points (usually 2 wk after inoculation), dispersed
cells from infected and uninfected lymphoid histocultures were
immunostained for cell surface markers CD3 and CD14 as de-
scribed previously (43). Cells were then fixed in 1% paraformal-
dehyde and subsequently permeabilized and immunostained for
intracellular CD68 and p24. 50,000–100,000 lymphocytes were
counted and the data were analyzed with CELLQuest™. Results
are reported as the mean with SEM.
 
Assessment of Viral Replication.
 
At the indicated time points, a
sample of culture media was withdrawn from infected tissue, di-
luted 1:1,000 with diluent, and stored at –20
 

 
C. The histoculture
 
media was then replaced. At the end of the experiment, samples
were thawed, and the concentration of HIV-1 p24 in the media
was measured by ELISA from NEN Life Science Products.
 
Results
 
Construction of Vpr-deficient Viruses.
 
To examine the tro-
pism and replication of Vpr-deficient viruses in lymphoid
tissue, we studied the matched pair of viruses, NL4–3 and
107. NL4–3 is a molecularly cloned strain of HIV-1 that ex-
hibits strict preference for the coreceptor CXCR4 and does
not replicate in macrophages (43, 45). 107 is a recombinant
virus derived from NL4–3 that shares the same genetic
backbone but incorporates coreceptor-determining enve-
lope sequences cloned from BaL, a CCR5-dependent pri-
mary HIV-1 isolate, as well as additional upstream se-
quences (45). These cloned sequences from BaL extend
through the 3
 

 
 end of 
 
vpr
 
 and, as a result of this substitution,
some minor differences exist in the amino acid sequences of
Vpr derived from NL4–3 and 107 (Fig. 1 A). However, the
genomes of NL4–3 and 107 are isogenic upstream of 
 
vpr
 
.
To assess the functionality of these proteins we transiently
transfected 293T cells with expression vectors encoding
HA-tagged NL4–3- or 107-derived versions of Vpr. West-
ern blot analysis with anti-HA mAb of whole-cell lysates
from these transfectants revealed slightly lower expression of
107 Vpr compared with NL4–3 Vpr (Fig. 1 B). Because
mutations or deletions in the 3
 

 
 end of 
 
vpr
 
 can alter expres-
sion levels of Vpr (48), we infer that the sequence differ-
ences between the NL4–3 and 107 
 
vpr
 
 genes may result in
stability differences between the two Vpr proteins leading to
differential expression. We next transfected 293T cells with
empty HA vector, NL4–3-derived, or 107-derived HA-Vpr
expression vectors and stained the cells for intracellular
DNA content 36 h later. Cell-cycle analysis by flow cytom-
etry revealed that both NL4–3- and 107-Vpr induced sig-
nificant G
 
2
 
 cell-cycle arrest, thereby establishing the func-
tionality of both NL4–3- and 107-Vpr in vitro (Fig. 1 C).
For the present studies, we wished to eliminate Vpr ex-
pression in NL4–3 and 107 viral clones for comparisons to
their respective parental viruses. We introduced a deletion
and two premature stop codons into the nucleotide se-
quence of 
 
vpr
 
 in both the NL4–3WT and 107WT proviral
contexts, thereby generating NL4–3
 

 
Vpr and 107
 

 
Vpr,
respectively (Fig. 1 D). Because NL4–3 and 107 have iden-
tical sequences upstream of the EcoR1 site used to delete
Vpr, this cloning strategy preserved the isogenicity between
NL4–3 and 107 including 
 
vif
 
 and 
 
pol
 
. Neither of these Vpr-
deficient viruses produced detectable quantities of the trun-
cated Vpr product (data not shown). Consistent with this
observation, immunoblot analysis of wild-type and mutant
virions established the presence of Vpr in NL4–3WT and
107WT virions but not in NL4–3
 

 
Vpr and 107
 

 
Vpr viri-
ons, confirming that Vpr was not expressed in the deletion
mutants (Fig. 1
 
 
 
E). We detected lower levels of Vpr within
107WT virions compared with NL4–3WT virions, consis-
tent with the inferred stability differences between these dif-
ferent versions of the proteins (Fig. 1 B). Comparing wild-
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type and Vpr-deficient versions of NL4–3 or 107 we subse-
quently examined the cellular tropism and replication pro-
files of these viruses within human lymphoid tissues ex vivo.
 
Vpr Is Not Required for Productive Infection of Resting T
Cells.
 
On the basis of morphologic characteristics we
have previously identified two distinct lymphocyte popula-
tions within lymphoid histocultures (47). We termed one
population of cells with small size, low granularity, and low
proliferative activity “lymphocytes.” The second popula-
tion, characterized by cells of greater size, increased granu-
larity, and significant proliferative activity, was termed
“blasts.” Although lymphocytes exhibit limited prolifera-
tion, our earlier studies have directly demonstrated produc-
tive infection of nondividing cells within this subset (47).
These results confirm that the virally infected T lympho-
cytes do not represent a subpopulation of dividing T cells
and establish that HIV-1 can productively infect nondivid-
ing lymphocytes de novo. To determine if Vpr contributed
to the infection of these nondividing cells, we inoculated
histoculture tissue with equivalent TCID
 
50
 
 of wild-type or
Vpr-deficient strains of NL4–3 or107. After a 7-d incuba-
tion, cells were harvested from the tissue and immu-
nostained for intracellular p24, a marker of productive HIV
infection. Examination of CD4
 

 
 T cells by FACS
 
®
 
 re-
vealed significant infection of both lymphocytes and blasts
by the wild-type and Vpr-deficient variants of NL4–3 and
107 (Fig. 2). As observed previously, NL4–3 infection re-
sulted in higher levels of productive infection than did 107
Figure 1. NL4–3- and 107-derived Vpr are functional and incorporated into mature viri-
ons. (A) HIV-1 Vpr from NL4–3 is identical to the BaL-derived, macrophage-tropic 107
variant except at residues 78 and 83–85. (B and C) DNA encoding HA-tagged NL4–3 Vpr
or 107 Vpr and GFP was transfected into 293T cells. (B) Cells were lysed 36 h later, and ex-
pression of Vpr was determined by Western blot with anti-HA mAb. (C) Cells were har-
vested 36 h later, and labeled with propidium iodide. DNA content was measured in GFP
cells by flow cytometry. (D) Cloning strategy for truncation of vpr within both NL4–3 and
107 proviral constructs. Note that the sequences of vif, pol, and tat are unaffected by these
mutations within vpr. The shaded box identifies the deleted region within vpr. (E) DNA en-
coding each of the HIV-1 recombinants was transfected into 293T cells and supernatants
were collected 48 h later. Virus production was normalized for p24 concentration, and equal
amounts of virus were concentrated for each strain by ultra-centrifugation. The viral pellet
was then subjected to Western blot analysis. Shown are representative experiments.
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due to a broad distribution of CXCR4 on target cells and
limited expression of CCR5. Most importantly, within a
given X4 (Fig. 2 A) or R5 (Fig. 2 B) proviral backbone,
wild-type and Vpr-deficient strains equivalently infected
the lymphocyte pool, suggesting that Vpr is not an essential
viral factor for the productive infection of nondividing or
dividing T cells in such tissue contexts. This finding was
unexpected given the putative role of Vpr in the nuclear
targeting of the PIC in nondividing cells such as tissue
macrophages. Wild-type and Vpr-deficient viruses likewise
equivalently infected the blast pool (Fig. 2, A and B). We
note that Vpr has been shown to have a greater influence
on HIV-1 infectivity at low titers, and only a small impact
at high multiplicity of infection (m.o.i.) (22). Importantly,
the experiments reported here were performed at a m.o.i.
below 2 
 
	
 
 10
 

 
4
 
, a very low inoculum, which likely ac-
counts for the 5-d delay in the appearance of detectable in-
tracellular and soluble p24 after inoculation. Experiments
performed with one-half the virus inoculum used above
also revealed no differences in the infection of CD4
 

 
 T
lymphocytes and blasts by wild-type or Vpr-deficient vi-
ruses under these conditions (data not shown).
 
We previously demonstrated by pulse-chase analysis that
naive and memory T cells in these tissues exhibited signifi-
cantly different proliferative activity (47). We therefore hy-
pothesized that while Vpr may not be necessary for infection
of T cells in general, it may nonetheless be a critical factor
for infection of the nonproliferating, naive T cell subset, a
population typically accounting for less than 20% of the total
CD4
 

 
 T lymphocyte population. To measure the cumula-
tive fraction of cycling T cells during a typical HIV infec-
tion, we cultured tonsil tissue in medium containing BrdU
for 7 d. FACS
 
®
 
 analysis of samples harvested after labeling
revealed that while greater than 16% of memory CD4
 

 
 T
lymphocytes incorporated BrdU during this period, only
2.3% of naive CD4
 

 
 T lymphocytes did so (Fig. 3 A). This
pattern of enhanced labeling of memory cells compared
with naive cells was preserved in the blast compartment as
well, although the blast subsets exhibited greater prolifera-
tive activity overall than did their lymphocyte counterparts.
We next compared the capacity of wild-type and Vpr-
deficient viruses to productively infect each of these subsets.
Tonsil histocultures were inoculated with equivalent titers
of X4 or R5 wild-type or Vpr-deficient viruses, and after a
Figure 2. HIV-1 infection of
CD4 T lymphocytes and blasts.
(A) Productively infected cell
subsets in tonsil tissue following
a 7-d infection with NL4–3WT
(white bars) or NL4–3Vpr
(black bars) as measured by intra-
cellular p24 expression detected
by FACS®. (B) Productively in-
fected cell subsets in tonsil tissue
after a 7-d infection with
107WT (white bars) or 107Vpr
(black bars). Presented are mean
values with SEM (n 
 3) from a
representative experiment.
Figure 3. BrdU incorpora-
tion and HIV-1 infection of na-
ive and memory CD4 T cell
subsets. (A) Tissue samples were
cultured continuously in me-
dium containing BrdU for 7 d.
Cells were isolated, immu-
nostained for CD4, CD62L,
CD45RA, and BrdU, and ana-
lyzed by FACS®. Shown are
mean values with SEM (n 
 3)
from a representative experi-
ment. (B and C) Tonsil histocul-
tures were inoculated with
equivalent titers of HIV-1, incu-
bated for 7 d, and harvested.
Cells were dispersed, immu-
nostained for p24, CD62L,
CD45RA, and CD4, and analyzed by FACS®. T cells were also stratified based on forward and side scatter properties defining lymphocyte and blast mor-
phologies. (B) Productively infected subsets in tissue inoculated with NL4–3WT or NL4–3Vpr as measured by intracellular p24 expression. (C) Pro-
ductively infected subsets in tissue inoculated with 107WT or 107Vpr. Shown are mean values with SEM (n 
 3) from a representative experiment.
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7-d incubation, cells were immunostained for maturation
markers and intracellular p24. Stratification of T cells into
memory and naive subsets revealed no statistically signifi-
cant differences between cultures infected with wild-type
or Vpr-deficient NL4–3 (Fig. 3 B) or 107 (Fig. 3 C) vari-
ants. Most importantly, this analysis demonstrated equiva-
lent infection of the nondividing, naive T lymphocyte pop-
ulation by the wild-type and Vpr-deficient viruses. This
finding substantiates our earlier conclusion that Vpr does
not contribute to lymphocyte infection in general, and spe-
cifically indicates that Vpr function is dispensable for pro-
ductive infection of the nonproliferating subset of T cells.
Vpr Does Not Trigger Cell-Cycle Arrest in Infected Lympho-
cytes Ex Vivo. We next sought to determine if Vpr in-
duces G2 cell-cycle arrest in these tissues. Tonsil histocul-
tures were inoculated with equivalent titers of NL4–3WT
or NL4–3Vpr virus, and after a 6-d incubation, the tonsil
tissue was harvested and stained for intracellular p24 and
DNA content. Samples were then analyzed by flow cytom-
etry; we gated on CD4 T cells and examined them for in-
tracellular p24 expression. Analysis of the DNA content of
p24 T cells in the samples inoculated with wild-type or
Vpr-deficient virus revealed a similar percentage of cells in
the G2 phase of the cell-cycle irrespective of the presence or
absence of Vpr (Fig. 4, A and C). Interestingly, in samples
inoculated with either wild-type or Vpr-deficient virus the
percentage of cells in G2 was modestly greater in the frac-
tion of productively-infected T cells (p24) (Fig. 4, A and
C) compared with uninfected T cells (p24) in the same
tissue (Fig. 4, B and D). Similar results were observed over
several different infections in lymphoid tissue, suggesting
that there is no detectable Vpr-dependent G2 cell-cycle ar-
rest and that other viral factors may play a key role in this
phenomenon.
Vpr Does Not Contribute to HIV-1–mediated Depletion of T
Cells in Lymphoid Histoculture. To determine directly if
equivalent infectivity correlated with equivalent cytopath-
icity, we measured virus-induced depletion of CD4 T
Figure 4. Cell-cycle analysis of p24 or p24 CD4 T cells. (A) Tonsil
specimens were inoculated with equivalent titers of HIV-1 NL4–3WT (A
and B) or NL4–3Vpr (C and D). After a 7-d incubation, samples were
dispersed, stained for intracellular p24, CD4, and To-Pro-3 iodide, and an-
alyzed by FACS®. DNA content is presented for cells stratified into p24 (A
and C) and p24 (B and D) fractions. Shown is a representative experiment.
Figure 5. Depletion of CD4 T cells by HIV-1 in lymphoid histocul-
ture. (A) After a 13-d infection, cells were isolated from histocultures and
immunostained for surface expression of CD4, CD3, CD8, and CCR5.
The mean CD4 subset/CD8 ratio relative to uninfected control tissue
for CCR5 T cells (white bars) and CCR5 T cells (black bars) was then
calculated. Shown are mean values with SEM (n 
 3) from a representative
experiment. (B and C) Depletion of naive and memory CD4 T cell sub-
sets by HIV-1. After a 12-d infection with NL4–3WT and NL4–3Vpr (B)
or 107WT and 107Vpr (C) cells were dispersed from histocultures and
immunostained for CD4, CD62L, CD45RA, and CD8. The mean CD4
subset/CD8 ratio relative to uninfected control tissue for memory T cells
(white bars) and naive T cells (black bars) was then calculated. Shown are
mean values with SEM (n 
 3) from a representative experiment.
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cells after infection with HIV-1. We began by subsetting
T cells based on expression of the HIV-1 coreceptor
CCR5. As expected from previous studies, NL4–3WT
extensively depleted both CCR5 and CCR5 subpopu-
lations of CD4 T lymphocytes (Fig. 5 A). Likewise,
NL4–3Vpr also markedly depleted both subpopulations
in a manner indistinguishable from its parental virus. In
contrast to the extensive depletion by NL4–3, the cyto-
pathic effects of 107WT were limited to the CCR5 sub-
set of CD4 T lymphocytes, as has been observed previ-
ously (41, 43). Again, the Vpr-deficient 107 strain
exhibited equivalent cytopathic activity compared with
wild-type 107. These findings demonstrate that Vpr is not
essential for the cytopathic effects of HIV-1 on CD4 T
cells within lymphoid tissues.
To determine further whether the state of T cell matu-
ration influences the susceptibility of these cells to deple-
tion by Vpr-deficient viruses, we measured the loss of na-
ive and memory CD4 lymphocytes after infections with
HIV-1. Both NL4–3WT and NL4–3Vpr induced severe
depletion of naive and memory CD4 lymphocytes (Fig.
5 B), although the cytopathic effects of NL4–3Vpr were
slightly reduced compared with that of NL4–3WT, con-
sistent with our earlier finding of slightly reduced infectiv-
ity of NL4–3Vpr. We also measured depletion in tissue
that had been inoculated with 107WT or 107Vpr. As is
characteristic of all R5 viruses, overall depletion was not
severe. Nevertheless, the degree of depletion of the mem-
ory and naive populations was equivalent for both 107
variants (Fig. 5 C). Thus, Vpr does not contribute to the
cytopathic activity of either HIV-1 R5 or X4 variants in
T lymphocytes.
Vpr Contributes Substantively to the Productive Infection of
Tissue Macrophages as well as to the Viral Burden in Lymphoid
Tissue. In addition to infecting activated T cells, R5 vi-
ruses also productively infect cells of the monocyte/mac-
rophage lineage. We therefore examined the putative role
of Vpr in mediating the infection of nondividing lym-
phoid tissue macrophages. We inoculated tonsil histocul-
tures with equivalent titers of 107WT or 107Vpr. After
incubation, the tissue was dispersed and cells were immu-
nostained for specific macrophage (CD14 and CD68) and
T cell (CD3) markers as well as intracellular p24. Because
macrophages associate tightly with B- and T cells in lym-
phoid tissues, macrophages free of complexed T cells
(CD14 or CD68 and CD3) were identified by flow
cytometry and analyzed for productive infection. In con-
trast to the behavior observed earlier in T cells, 107Vpr
exhibited a greater than fourfold reduction in infectivity in
lymphoid tissue macrophages compared with 107WT
(Fig. 6 A). A similar examination of the same tissue inocu-
lated with NL4–3WT and NL4–3Vpr revealed little de-
tectable infection within macrophages by either virus (data
not shown). These findings imply that Vpr contributes sig-
nificantly to the productive infection of tissue macro-
phages by R5 strains.
Interestingly, within the genomes of HIV-2 and SIV the
arrest and nuclear import functions of HIV-1 Vpr are di-
vided between two related gene products, Vpr and viral
protein X (Vpx) (49). Cell-cycle arrest is mediated by Vpr
in both HIV-2 and SIV, whereas nuclear localization is
mediated by Vpx in both species. The significance of this
functional division is not well understood; however, the
evolutionary conservation of both functions implies their
importance in the viral life cycle. To determine if the mac-
rophage-specific defect we observed in 107Vpr was spe-
cifically attributable to the nuclear entry activity of Vpr,
we inoculated tonsil samples with SIV PBj6.6WT,
PBj6.6Vpx or PBj6.6Vpr. Cells were later dispersed and
stained for macrophage-lineage markers and intracellular
p27. FACS® analysis revealed a greater than sixfold reduc-
tion in the number of productively infected macrophages
in tissue that had been inoculated with PBj6.6Vpx, com-
pared with tissue infected with wild-type virus (Fig. 6 B),
consistent with a role for Vpx in nuclear targeting. In con-
trast, tissue infected with PBj6.6Vpr showed no signifi-
cant decrease in the frequency of infected macrophages
(Fig. 6 B). Indeed, across several experiments the frequency
was either unchanged or modestly increased compared
with PBj6.6WT. Therefore, these results implicate the nu-
Figure 6. Flow cytometric
analysis of HIV-1 and SIV infec-
tion of macrophages in lymphoid
tissue. After a 9-d incubation with
107WT or 107Vpr (A) or
PBj6.6WT, PBj6.6Vpr or
PBj6.6vpx (B), cells were dis-
persed and immunostained for
surface expression of CD3 and
CD14 as well as intracellular
CD68 and p24 or p27. Shown are
mean values with SEM (n 
 3)
from a representative experiment.
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clear targeting function of HIV-1 Vpr in the infection of
macrophages by R5 HIV-1.
Finally, we measured the extent and kinetics of viral rep-
lication of wild-type and Vpr-deficient viruses in lymphoid
histocultures. Tissue was inoculated with equal titers of
NL4–3WT or NL4–3Vpr (Fig. 7 A) as well as 107WT or
107Vpr (Fig. 7 B). Supernatants were collected serially
throughout 18-d incubations, and the concentrations of p24
in the media were assessed by ELISA. As expected from
their strict T cell tropism and the earlier findings of similar
infectivity, NL4–3WT and NL4–3Vpr exhibited similar
replication profiles (Fig. 7 A). Both the overall growth ki-
netics as well as the total virus production were similar. In
contrast, a substantially different pattern of replication was
found for 107WT compared with 107Vpr. 107Vpr ex-
hibited an 50% reduction in viral replication compared
with 107WT (Fig. 7 B). Based on the selective effects of
Vpr we observed earlier in macrophages rather than T cells,
we infer that the differential viral output in tissues infected
with 107Vpr compared with 107WT is the result of de-
creased macrophage infection by Vpr-deficient viruses.
Thus, these results reveal the significant contribution of tis-
sue macrophages to the viral burden within human lym-
phoid tissues. Consistent with this conclusion, quantitation
of soluble p27 in the culture media of the SIV-infected tis-
sues revealed an eightfold reduction in viral output from tis-
sues inoculated with the Vpx-deficient strain of PBj6.6
compared with the wild-type and Vpr-deficient counter-
parts (data not shown). Thus, the Vpx-deficient SIV strain
behaved similarly to the Vpr-deficient R5 HIV-1 strain.
Overall, these results suggest that the major role of Vpr in
HIV-1 pathogenesis is to facilitate infection of macrophages,
a population that may also contribute substantially to the vi-
ral burden in infected individuals.
Discussion
Peripheral blood mononuclear cells in culture typically
require exogenous stimulation in order to support produc-
tive infection by either wild-type or Vpr-deficient viruses.
This dependency on activation appears to relate to the nu-
clear membrane breakdown associated with activation-
induced cellular division, which evidently abrogates the
need for Vpr to facilitate nuclear import of the PIC. In con-
trast, T cells within the lymphoid tissue microenvironment are
permissive for productive HIV-1 infection independent of
exogenous stimulation or cytokines. Moreover, our previ-
ous studies have revealed no absolute restriction to HIV-1
infection, replication, or depletion of T cells within these
cultures on the basis of target cell maturation or prolifera-
tion (47). In particular, these studies demonstrated de novo
infection and depletion of resting, naive lymphocytes,
which may explain the observation of productively in-
fected resting T cells in vivo (50–52). Because these cells
divide very infrequently (Fig. 3), infection must proceed
independently of nuclear membrane dissolution. Multiple
determinants of nuclear import contribute to this unique
property of HIV. The apparent redundancy of mechanisms
highlights the importance of nuclear entry in the HIV-1
life cycle. However, it is possible that individual import
signals may play a more or less dominant role in particular
cellular contexts. Thus, the multiple nuclear import signals
may not be redundant after all. We therefore examined the
importance of one such nuclear import signal, Vpr, in me-
diating nuclear import in diverse primary cell types includ-
ing nondividing T cells and macrophages.
Surprisingly, these studies revealed equivalent infection
of resting, naive T cells within histocultures inoculated
with matched wild-type or Vpr-deficient HIV-1 strains de-
spite differential infection of macrophages. This finding
suggests that other host or viral factors contribute to the
nuclear import of the PIC in this subset of nondividing T
lymphocytes. At least two additional viral gene products
may be responsible. We speculate that the weak nuclear lo-
calization signals (NLS) within MA (19–21) may function
relatively efficiently within T cells, which would reduce
the dependence on Vpr-mediated translocation mecha-
nisms. In addition, multiple NLS have also been identified
Figure 7. Kinetic analysis of
HIV-1 replication in lymphoid
histoculture. Tissue was inoculated
with NL4–3WT or NL4–3Vpr
(A) or 107WT or 107Vpr (B).
Culture medium was sampled at
the indicated time points and
HIV-1 p24 concentration was
measured by ELISA. Shown are
mean values with SEM (n 
 3)
from a representative experiment.
1415 Eckstein et al.
within viral IN (22–24) that may also be relatively effective
in T cells. In particular, a novel NLS within IN has re-
cently been shown to contribute significantly to the infec-
tion of dividing as well as growth-arrested cells (24). Fi-
nally, the nucleophilic properties of the central DNA flap
may also play a more significant role in the nuclear import
of the PIC within infected T cells (25). Thus, the individ-
ual nuclear import signals within the PIC may each be op-
timized for a specific primary cell type.
The significance of other Vpr functions in viral expan-
sion is less clear. For example, our analysis of infected lym-
phoid cultures failed to detect specific G2 cell-cycle arrest
in samples inoculated with wild-type HIV-1 compared
with Vpr-deficient virus, suggesting that Vpr-dependent
arrest is not manifest in this tissue context. These observa-
tions are also supported by equivalent virus replication of
X4 viruses irrespective of the presence of Vpr. Alterna-
tively, it is possible that cells arrested in G2 by Vpr may be
rapidly and selectively eliminated within lymphoid histo-
cultures thereby preventing their detection. However,
these studies did reveal a modest accumulation of p24
cells in the G2 phase of the cell cycle in HIV-1–infected
cultures independent of Vpr status. This finding implies
that selective elimination of Vpr-arrested cells is not a
likely feature of this system and suggests that viral factors
in addition to Vpr may contribute to arrest in this tissue
context. Indeed, a previous study has demonstrated that
envelope glycoprotein may induce arrest in cultured cells
(53). The individual contributions of these two pathways
remain to be determined.
We also detected equivalent depletion of T cells by
wild-type and Vpr-deficient HIV-1 variants. Although ear-
lier studies have reported a pro-apoptotic role for Vpr, our
findings suggest that Vpr is not required for such effects in
lymphoid tissue. Indeed, mutagenesis studies have revealed
that the apoptotic function ascribed to Vpr seems to segre-
gate with the cell-cycle arrest activity (36), and we have
found that neither activity is evident in these histocultures.
We conclude that neither cell-cycle arrest nor apoptosis in-
duced by Vpr contribute significantly to virus-induced T
cell death in this context.
The identical replication kinetics of wild-type and Vpr-
deficient X4 viruses within lymphoid tissue is consistent
with our earlier conclusions regarding X4 HIV-1 infection
and depletion. However, we note that a slight trend toward
reduced replication by Vpr-deficient strains was evident
from these studies, which may correlate with the observed
trend toward slightly reduced infectivity and depletion by
Vpr-deficient X4 virus. Although few of these differences
reached statistical significance, these patterns were observed
in multiple tissue specimens, which may indicate a small
contribution of Vpr to the fitness and replication of X4
HIV-1 strains in vivo.
In contrast to the behavior of cultured peripheral blood
T cells (2, 4, 54), monocyte-derived macrophages matured
in vitro depend substantially on intact Vpr for productive
infection (2, 4, 6, 55). However, this effect is evident only
at very low multiplicity of infection and only after weeks of
in vitro culture. Indeed, some investigators have observed
no effect of Vpr on infection of cultured monocyte-derived
macrophages (56). In addition, an important issue that re-
mains unanswered by these studies is the importance of Vpr
for infection of macrophages residing within lymphoid tis-
sues. Lymphoid organs are the principal sites of HIV-1 rep-
lication in vivo and account for 90% of the viral load
during HIV-1 infection (57), particularly during the acute
and asymptomatic phases of disease when viruses selectively
using CCR5 predominate. CCR5 is expressed on most tis-
sue macrophages, dendritic cells, and a subset of activated T
cells. The selection of CCR5-dependent viruses during
acute infection suggests that macrophage infection may be
a key factor in the establishment of HIV-1 infection as well
as the subsequent development of functional immunodefi-
ciency. We therefore examined the role of Vpr in the es-
tablishment of HIV-1 infection in tissue-resident macro-
phages rather than artificially matured blood-derived cells.
Our results revealed a substantial defect in the productive
infection of macrophages by Vpr-deficient viruses, which
stands in sharp contrast to its lack of effect in T cells. This
macrophage-restricted phenotype was also apparent in tis-
sues inoculated with Vpx-deficient, but not Vpr-deficient,
strains of SIV. These observations confirm the specific im-
portance of nuclear import in the life cycle of HIV-1 and
SIV within macrophages. Furthermore, these findings sug-
gest that the nuclear import signals within the viral PIC
may be cell type specific and may not be completely redun-
dant in all cellular environments. Indeed, each NLS within
the PIC may be conserved so as to preserve the ability of
HIV-1 to productively infect distinct cell types. We con-
clude that Vpr contributes substantially to the replication of
R5 HIV-1 within macrophages but does not play a signifi-
cant role in T cells.
Recent in vitro work has demonstrated that HIV-1 Nef
expression within macrophages induces production of the
soluble CC-chemokines macrophage inflammatory pro-
tein-1 and -1 and other unidentified soluble factors (58).
These chemokines may recruit and partially activate neigh-
boring resting lymphocytes and thereby render them per-
missive for infection by HIV-1, which would assign infec-
tion of macrophages an important role in establishing
infection in resting lymphocytes. Selective impairment of
macrophage infection, as is seen with the Vpr-deficient vi-
ruses tested here, would be expected to interrupt this trans-
activating function. However, this effect was not evident in
the histoculture system. Specifically, the frequency of in-
fected resting, naive T cells by 107Vpr or NL4–3Vpr
was identical to that of their wild-type counterparts.
Therefore, experimental conditions or viral factors other
than, or in combination with, Nef may play key roles in
the ability of HIV-1 to infect resting, naive lymphocytes in
a lymphoid tissue microenvironment.
Finally, macrophages may contribute substantially to
plasma viral load during late infection, particularly when
CD4 T cells have been extensively depleted (57, 59, 60).
However, the contribution of macrophages to viral load
during other disease stages has not been well characterized
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but is proposed to be minimal based on the viral and cellu-
lar kinetics observed during acute antiviral treatment (61–
64). Based on the assumption that HAART completely
suppresses virus replication, such studies suggest that plasma
viremia declines with a half-life of 1 d, implying that the
cells releasing virus into the plasma must have a similar half-
life. This conclusion implicates T cells as the principle
source of plasma viremia rather than infected tissue macro-
phages, which are believed to have a half-life of nearly 2
wk (61–64). However, more recent studies have generated
evidence of other persistent viral reservoirs that may con-
tribute to plasma viremia (65–68). The studies reported
herein address this controversy directly by examining the
replication kinetics of viruses that fail to infect macrophages
productively while their capacity to infect and replicate
within lymphocytes is preserved. Thus, any difference in
viral output may be interpreted as the contribution of mac-
rophage infection. The results reveal a significant reduction
in the concentration of soluble p24 in cultures infected
with 107Vpr as compared with wild-type virus. This
finding is correlated with a greater than fourfold reduction
in the frequency of infected macrophages and preserved
numbers of infected T cells in these same samples. We
therefore conclude that the differential output between
cultures infected with wild-type and Vpr-deficient R5 vi-
ruses is attributable to the output of the productively in-
fected macrophage pool.
This conclusion implies that within lymphoid organs in-
fected with R5 viruses the contribution to cell-free virus
by infected macrophages is equal to that of all infected
CCR5CD4 T cells within the particular tissue—a popu-
lation that significantly outnumbers tissue macrophages by
at least 10-fold. Therefore, on a per-cell basis, we infer that
productively infected macrophages cumulatively release at
least 10-fold more p24 than do productively infected T
cells within the same tissue over the 2-wk time interval of
these experiments. Thus, it appears that HIV replication
within macrophages contributes significantly to tissue viral
burden and may account for a substantial fraction of plasma
viremia to the extent that plasma virus derives from tissue
sources. However, it remains a theoretical possibility that T
cells infected by macrophage-derived virus or in the prox-
imity of infected macrophages may produce more p24 than
cells infected by T cell–derived or cell-free virus. Never-
theless, our conclusions agree well with recent work dem-
onstrating significant and sustained plasma viremia in
SHIV-infected macaques after virus-induced depletion of
CD4 T cells, in which the authors concluded that the
viremia was supported by viral replication in productively
infected macrophages (60). Our results extend this observa-
tion by demonstrating the significant contribution of hu-
man lymphoid macrophages to HIV-1 viral burden even
when T cells are present.
Given the close physical association between macro-
phages and T cells within lymphoid organs, it is possible
that the majority of virus produced by macrophages may be
transmitted to neighboring lymphoid cells by means of cell-
to-cell spread. Virus produced by macrophages and trans-
mitted in this manner may not contribute substantially to
the cell-free virus detected in the plasma. As a conse-
quence, the dynamics of viral decline within lymphoid tis-
sues may differ from that of the plasma. Although few in
number, productively infected lymph node macrophages
have in the past been thought to play a large role in viral
burden (57, 59). Our findings underscore the potential im-
portance of this relatively small cellular reservoir of virus.
Spread of R5 virus directly from macrophages to T cells
might contribute substantially to HIV-induced immune
pathogenesis during the early and asymptomatic stages of
HIV-induced disease, as well as later stages of disease when
T cells have been depleted. Tissue macrophages may there-
fore represent a clinically important cellular reservoir of vi-
rus, as macrophage-derived virus would be expected to
contribute substantially to the progressive attrition of T
cells that characterizes all stages of HIV disease.
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